AcelRx Pharmaceuticals (NASDAQ:ACRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a research note published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently commented on ACRX. Alliance Global Partners assumed coverage on AcelRx Pharmaceuticals in a research report on Monday, October 2nd. They set a buy rating and a $4.25 price target on the stock. HC Wainwright dropped their price target on AcelRx Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a research report on Monday, September 25th.

AcelRx Pharmaceuticals Trading Up 1.3 %

ACRX stock opened at $0.50 on Friday. The stock’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $0.87. AcelRx Pharmaceuticals has a 1-year low of $0.43 and a 1-year high of $2.78. The stock has a market cap of $8.49 million, a P/E ratio of -0.22 and a beta of 0.44.

Institutional Trading of AcelRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ACRX. Vanguard Group Inc. raised its stake in shares of AcelRx Pharmaceuticals by 22.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,569,553 shares of the specialty pharmaceutical company’s stock valued at $955,000 after purchasing an additional 831,999 shares during the period. Armistice Capital LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 4th quarter valued at $830,000. Virtu Financial LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $29,000. Cowen AND Company LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter valued at $67,000. Finally, Values First Advisors Inc. raised its stake in shares of AcelRx Pharmaceuticals by 201.7% during the 2nd quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock valued at $136,000 after purchasing an additional 81,854 shares during the period. 19.79% of the stock is currently owned by institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.